IDiyas

For the Inventor, By the Inventor

Indianapolis, IN, United States of America

Gary G Marconi

USPTO Granted Patents = 10

Average Co-Inventor Count = 2.9

ph-index = 5

Forward Citations = 67(Granted Patents)


Company Filing History:

goldMedal10 out of 4,442 
 
Eli Lilly and Company
 patents

Years Active: 1976-1996

Loading Chart...
10 patents (USPTO):Explore Patents
1. 5534420 - Biotransformation of glycopeptide antibiotics (1996-07-09),
2. 4717714 - A-51568B antibiotic (1988-01-05),
3. 4558009 - Process for producing antibiotic A-51568 by fermentation and (1985-12-10),
4. 4558008 - Process for production of A-51568B antibiotic (1985-12-10),
5. 4495179 - A51568 Antibiotic and process for producing thereof (1985-01-22),
6. 4204039 - Process for producing deoxynarasin antibiotics (1980-05-20),
7. 4174404 - Deoxynarasin antibiotics (1979-11-13),
8. 4141907 - Deoxynarasin antibiotics (1979-02-27),
9. 3986928 - Antibiotic A-32390 and process for preparation thereof (1976-10-19),
10. 3979433 - 1,6-Di-O-(2-isocyano-3-methylcrotonyl)-D-mannitol compounds (1976-09-07),

Title: Gary G Marconi: Innovator in Glycopeptide Antibiotics

Introduction

Gary G Marconi is a prominent inventor based in Indianapolis, IN (US), known for his significant contributions to the field of antibiotics. With a total of 10 patents to his name, Marconi has made remarkable advancements in the biotransformation of glycopeptide antibiotics.

Latest Patents

Among his latest patents is the innovative method for the biotransformation of glycopeptide antibiotics. This patent details the preparation of new glycopeptides derived from a vancomycin-type antibiotic using an Acinomadura citrea culture (NRRL 18382). These biotransformed intermediates serve as useful components in antibiotic development. Another notable patent is for the antibiotic A-51568B, which is produced through submerged, aerobic fermentation of Nocardia orientalis NRRL 15232. A-51568B has demonstrated effective antibiotic activity against gram-positive bacteria, showcasing Marconi's impact on antibiotic research.

Career Highlights

Gary G Marconi is currently associated with Eli Lilly and Company, where he continues to innovate in the field of pharmaceuticals. His work has been instrumental in developing new antibiotics that address critical health challenges.

Collaborations

Marconi has collaborated with notable colleagues, including Marvin M Hoehn and Walter M Nakatsukasa, contributing to the advancement of antibiotic research and development.

Conclusion

Gary G Marconi's work in the field of glycopeptide antibiotics exemplifies his dedication to innovation and research. His patents and collaborations have significantly impacted the pharmaceutical industry, particularly in the development of effective antibiotics.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…